---
title: "安徽華人健康醫藥股份有限公司 (301408.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/301408.SZ.md"
symbol: "301408.SZ"
name: "安徽華人健康醫藥股份有限公司"
industry: "藥品零售商"
---

# 安徽華人健康醫藥股份有限公司 (301408.SZ)

| Item | Detail |
|------|--------|
| Industry | 藥品零售商 |
| Location | 滬深市場 |
| Website | [www.hrjkjt.com](https://www.hrjkjt.com) |

## Company Profile

公司成立于 2001 年，總部位于安徽省合肥市。採用以產品加賦能為特色的醫藥代理營銷模式，建立了覆蓋全國的營銷網絡，深受市場歡迎。公司聚焦醫藥終端 1 個核心領域，圍繞產品矩陣和藥店終端 2 個方向，通過藥店商學院、數智研究院、藥物研究院 3 大引擎，打造醫藥零售、醫藥代理、研發生產、終端集採 4 大業務平台，形成了各業務板塊均衡發展、良性協同、優勢互補的醫藥生態型企業，完成從單一醫藥銷售向全價值鏈健康服務的躍遷。企業榮譽：安徽著名品牌、2011-2012 年度守合同重信用單位、2018 年榮獲 2018 年度市級 “雙強六好” 非公企業黨組織、2017 年榮獲 2017 年度包河區 “雙強六...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:09.000Z

**Overall: B (0.33)**

**Industry**: Drug Retail

| Metric | Value |
|--------|-------|
| Industry Ranking | 2 / 9 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 17.47% |  |
| Net Profit YoY | 38.58% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.78 |  |
| Dividend Ratio | 0.51% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 7.92B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 5.15B |  |


**Multi Score**: B

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 9.16% | B |
| Profit Margin | 3.62% | C |
| Gross Margin | 33.68% | C |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 17.47% | B |
| Net Profit YoY | 38.58% | B |
| Total Assets YoY | 8.22% | B |
| Net Assets YoY | 6.67% | B |

#### Cash Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 2764.06% | A |
| OCF YoY | 17.47% | B |

#### Operating Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 1.00 | A |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 59.77% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 安徽華人健康醫藥股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "9.16%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "3.62%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "33.68%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "17.47%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "38.58%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.22%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "6.67%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "A",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "2764.06%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "17.47%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "A",
      "indicators": [
        {
          "name": "Turnover",
          "value": "1.00",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "59.77%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 益豐藥房 (SH.603939) | B | C | A | C | B | B |
| 02 | 華人健康 (SZ.301408) | B | B | A | D | A | B |
| 03 | 第一醫藥 (SH.600833) | C | C | A | C | B | B |
| 04 | 大參林 (SH.603233) | B | C | A | D | B | C |
| 05 | 老百姓 (SH.603883) | C | D | A | D | B | C |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 42.47 | 6/9 | 39.81 | 34.51 | 31.10 |
| PB | 3.78 | 8/9 | 3.13 | 2.67 | 2.39 |
| PS (TTM) | 1.54 | 9/9 | 1.31 | 1.13 | 1.04 |
| Dividend Yield | 0.51% | 7/9 | 0.83% | 0.73% | 0.60% |

## References

- [Company Overview](https://longbridge.com/en/quote/301408.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/301408.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/301408.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.